Vizimpro
What Vizimpro is used for
Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Vizimpro
- Active substance
- dacomitinib
- Disease area
- Carcinoma, Non-Small-Cell Lung
- Medicine group
- Antineoplastic agents
- ATC code
- L01EB07
- Marketing authorisation holder
- Pfizer Europe MA EEIG
- Authorised in the EU since
- 2019
Official information
In India
- Dacomitinib monohydrate: 3 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Vizimpro used for?
Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.
What is the active substance in Vizimpro?
Vizimpro contains dacomitinib.
Who makes Vizimpro?
The EU marketing authorisation holder is Pfizer Europe MA EEIG.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU